Ophthalmic complications of immune checkpoint inhibitors

ABSTRACT

Purpose

Immune checkpoint inhibitors are a relatively new class of medications that activate normal tumor surveillance mechanisms. These agents have tremendous utility in treating a variety of cancers and are thus being used with increasing frequency. However, these medications carry significant ophthalmic toxicities. This review aims to discuss the most common ocular side effects of immune checkpoint inhibitors.

Methods

A literature search was performed to identify reports of ophthalmic side effects of immune checkpoint inhibitors. The articles were reviewed, and data was extracted.

Results

Immune checkpoint inhibitors may result in a wide variety of ophthalmic complications, including ocular surface disease, uveitis, orbital inflammation, myositis and myopathy, optic nerve disease, and chorioretinal lesions. While many of these toxicities respond to topical and systemic corticosteroids, more severe presentations necessitate temporary or permanent discontinuation of therapy.

Conclusions

This class of medication may yield a spectrum of ocular side effects, and ophthalmologists must be cognizant of these problems and their implications. Patient education facilitates appropriate vigilance and awareness of these issues. Coordination with the oncologic team will help to determine optimal treatment strategies.

KEYWORDS:

• immune checkpoint
• immunotherapy
• checkpoint inhibitor
• complication

Disclosure statement

The authors do not have any financial conflicts of interest to disclose.